A randomised, placebo-controlled trial investigating the role of fampiridina in cerebral circuits involved in cognitive and motor function of patients with multiple sclerosis.

Trial Profile

A randomised, placebo-controlled trial investigating the role of fampiridina in cerebral circuits involved in cognitive and motor function of patients with multiple sclerosis.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2017 This study has been completed in Italy as per European Clinical Trials Database.
    • 28 Apr 2017 Primary endpoint (Improvement in the SDMT score) has been met, according to results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to results presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top